Final Activity Report Summary - EVATTUM (Ex vivo assessment of therapy for brain tumors)
The results of this technology transfer project were as follows:
1) The INSERM ISIS platform was transferred to Capsant Neurotechnologies. This involved training of Capsant staff by INSERM staff. The appropriate equipment was bought in and set-up at Capsant. Different cell lines were tested in the system along with different tissue sources for preparing the slice platform.
2) Using specialised software, the platform was validated for low throughput quantification of morphological differences between different types of tumours and treatments.
3) The system was validated for low-throughput screening for anti-tumour drugs.
4) The platform was analysed and improved for developing the ISIS platform for industrial use.
5) High throughput quantification systems were assessed for industrial use.